


PATENT
ATTORNEY DOCKET NO. 50164/026005

Certificate of Mailing: Date of Deposit: November 29, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Seth Kellogg

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jost-Price et al.

Confirmation No.: 6701

Serial No.: 10/777,517

Art Unit: 1614

Filed: February 12, 2004

Examiner: Michel Graffeo

Customer No.: 21559

Title: METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES
AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF
PROINFLAMMATORY CYTOKINES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned case on June 29, 2007, Applicants elect the invention of Group II, the SSRI species of paroxetine, the corticosteroid species of prednisolone, the additional agent species of DMARD, and the disorder species of rheumatoid arthritis. The claims that read on the elected species are claims 25-28 and 30, 31, 35, and 45-50. The election is made without traverse.

If there are any charges or any credits, please apply them to Deposit Account No.


03-2095.

Respectfully submitted,

Date: 11/29/04

 Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045


Michael Bell, Jr., Ph.D.
Reg. No. 52,608